+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers



Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers



Clinical Pharmacology and Therapeutics 59(4): 450-457



Objective: To evaluate the effects of simultaneous pharmacologic inhibition of catechol-O-methyltransferase (COMT) and monoamine oxidase type A (MAO-A) on hemodynamics and catecholamine metabolism in healthy volunteers at rest and during exercise. Background: Entacopone, a COMT inhibitor, is studied as an adjunct to levodopa treatment in patients with Parkinson's disease. Moclobemide, an MAO-A inhibitor, is already in clinical use as an antidepressant. It is likely that entacapone and moclobemide will be used concomitantly in the future in patients who have both Parkinson's disease and depression. It was therefore considered to be important to investigate the tolerability of combined COMT and MAO-A inhibition with entacapone and moclobemide. Design and methods: This was a randomized, single-dose, double-blind crossover study of 12 healthy male volunteers. The treatments were either placebo, 200 mg entacapone, 150 mg moclobemide, or the combination of entacapone and moclobemide in single doses. Heart rate, blood pressure, impedance cardiography, and plasma concentrations of catecholamines and their metabolites were measured both at rest and during submaximal standardized bicycle exercise. Results: Entacapone and moclobemide (either alone or in combination) did not change heart rate, blood pressure, or any hemodynamic parameter at rest or during exercise compared with placebo. Neither were the concentrations of norepinephrine and epinephrine in plasma influenced. Both drugs had the expected effects on catecholamine metabolite concentrations in plasma. The decrease in the concentration of 3-methoxy-4-hydroxyphenylglycol (MHPG) induced by modobemide was not potentiated by entacapone. Conclusion: The combined use of therapeutic single doses of entacapone and moclobemide in healthy volunteers did not affect the hemodynamics or concentrations of unconjugated norepinephrine and epinephrine in plasma. Other mechanisms are capable of regulating the concentrations of norepinephrine and epinephrine in circulating blood (and apparently also at their receptors in the heart and vascular tissue) when both COMT and MAO-A activity are inhibited to a significant extent. This was also the case during marked sympathetic stimulation. The changes in the catecholamine metabolite concentrations provide evidence of effective COMT and MAO inhibition. Concentrations of MHPG in plasma are determined mainly by MAO-A activity because COMT inhibition did not have an additional effect on the moclobemide-induced decrease in plasma MHPG.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047374247

Download citation: RISBibTeXText

PMID: 8612391

DOI: 10.1016/s0009-9236(96)90115-0


Related references

Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Clinical Pharmacology and Therapeutics 48(4): 356-364, 1990

Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. British Journal of Clinical Pharmacology 27(2): 243-256, 1989

Effects of long-term administration of pyrogallol on tissue catecholamine levels, monoamine oxidase and catechol-O-methyltransferase activities in the rat. Biochemical Pharmacology 15(12): 1935-1946, 1966

Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. European Journal of Pharmacology 334(1): 31-38, 1997

Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochemistry International 56(6-7): 774-779, 2010

The simultaneous function of catechol-O-methyltransferase and monoamine oxidase in human placenta. Acta Obstetricia et Gynecologica Scandinavica 53(1): 41-47, 1974

Consequences of monoamine oxidase inhibition: increased vesicular accumulation of dopamine and norepinephrine and increased metabolism by catechol-O-methyltransferase and phenolsulfotransferase. Progress in Neuro-Psychopharmacology and Biological Psychiatry 13(3-4): 563-568, 1989

Metabolism of adrenaline after blockade of monoamine oxidase and catechol-O-methyltransferase. Science 133(3452): 586-587, 1961

COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. International Journal of Clinical Pharmacology and Therapeutics 32(11): 582-588, 1994

Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: Relationships to monoamine metabolite concentrations in CSF of healthy volunteers. European Archives of Psychiatry and Clinical Neuroscience 247(6): 297-302, 1997

Determination of monoamine oxidase and catechol o methyltransferase activity in the platelets of healthy people from various age groups. Fiziologiya Cheloveka 12(2): 316-321, 1986

Role of monoamine oxidase and catechol-O-methyltransferase in the metabolism of renal dopamine. Journal of Neural Transmission. Supplementum 41: 101-105, 1994

Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. Journal of Pharmacology and Experimental Therapeutics 268(3): 1242-1251, 1994

Inhibition of catechol o methyltransferase activity with entacapone does not affect hemodynamics of plasma catecholamine levels during exercise. Neurology 42(4 Suppl. 3): 324, 1992

Metabolism of centrally released noradrenaline by extraneuronal monoamine oxidase and catechol-O-methyltransferase. Brain Research 106(2): 403-406, 1976